16 June 2021
The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has found that a monoclonal antibody combination developed by US company Regeneron reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response.
11 June 2021
Seven researchers based at the University of Oxford have today been honoured as part of Her Majesty the Queen’s Birthday Honours List. The researchers have all played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments, findings which have saved many lives.
28 May 2021
The University of Oxford has today announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. The Pandemic Sciences Centre will harness the strong global research collaborations that the University of Oxford has developed over more than forty years. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats
20 May 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has been named David Sackett Trial of the Year by the Society for Clinical Trials (SCT). The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.
17 May 2021
The partnership will enable global genomic sequencing and examination through a specialist platform developed on Oracle Cloud Infrastructure to help mitigate the impact of potentially dangerous COVID-19 variants
12 May 2021
The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship five of which are from the Nuffield Department of Medicine. All were selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society
7 May 2021
Six scientists from the University of Oxford have joined the Royal Society as Fellows
National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines
23 April 2021
Data from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population
6 April 2021
The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19
23 March 2021
The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom
5 March 2021
NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts’ (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world
18 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said ‘The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies".
10 February 2021
Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found
Lateral flow devices detect most infectious COVID-19 cases and could allow a safer relaxation of the current lockdown
21 January 2021
Researchers from NDM's Big Data Institute working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious
19 January 2021
A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI)
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK
14 December 2020
RECOVERY reports absence of a benefit from Azithromycin. The latest result from the NDM/NDPH RECOVERY trial shows the widely administered administration of a broad-spectrum antibiotic makes no difference to the routine outcome in hospitalised COVID19 disease. Results on other therapies are likely to follow in the coming weeks.
11 December 2020
Data from the National COVID-19 Infection Survey, done in partnership between the University of Oxford, the Office of National Statistics, Public Health England, University of Manchester and the Wellcome Trust, has revealed detailed characteristics of England’s coronavirus pandemic, including which factors have contributed most to case numbers over different phases and the prevalence of asymptomatic infections.